International Journal For Multidisciplinary Research · Jun 16, 2026

Toward Cellular Immortality: A Biotechnological Perspective on Radical Human Longevity

By Caussy R

Aging slowly wears down our cells, tissues, and organs through things like shrinking telomeres, glitchy mitochondria, unstable DNA, and shifting gene activity. Telomeres, those chromosome end-caps, shorten with every cell division until cells hit senescence and quit working right. The enzyme telomerase can fix them, and lab tests like mouse studies show it delaying age-related decline. Biotech is pushing boundaries with telomerase therapies, senolytic drugs to clear zombie-like senescent cells, stem cells for tissue repair, Yamanaka factor reprogramming, and targeted nanotech delivery. Promising results include longer mouse lifespans from telomerase tweaks and better health from drug combos like dasatinib plus quercetin. But true immortality? Not even close. Aging's nine interconnected hallmarks mean fixing one issue uncovers others. This research review dives into aging's key drivers, telomere breakthroughs, anti-aging biotech strategies, why forever-young isn't feasible yet, and thorny ethical dilemmas like access inequality, overpopulation, and what super-long lives mean for society and our sense of self.

doi.org/10.36948/ijfmr.2026.v08i03.80967 Open access Interventions